GSK Will Promote Fraxiparine and Arixtra With Its Current Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will take on a few product development people from Sanofi if the deal goes through. GSK remains mum on possible development plans for Arixtra, citing competitive concerns with Sanofi-Aventis.